Professor Terry Hamblin (RIP 1943-2012)

Terry Hamblin
Quite simply a legend.

Born in Worcester, England, he was a medical student and junior doctor at Bristol University. He was appointed Consultant Haematologist in Bournemouth 1974-2003, Professor of Immunohaematology in Southampton 1986-2012, and Honorary Consultant Haematologist at Kings College Hospital, London 2004-2012.

He was awarded the Binet-Rai medal for outstanding research in CLL in 2002. Although he felt that this was his most successful area of research, Terry made significant contributions in the field of the Myelodysplastic Syndromes. He was instrumental in the International MDS Foundation, was a founder Member of the Executive Committee and Trustee of the UK MDS Forum, and published widely in the area.

Probably unknown now to many, he worked closely with Professor Mufti to publish one of the first MDS prognostic scores, fondly referred to as 'The Bournemouth Score', published in 1985.

Terry was a huge character, an amazing clinician, successful scientist and a wonderful colleague. He will always be missed. It is our wish to remember our friend by holding an Annual Lecture in his name. Please join us to celebrate his life and join us in a scientific debate that was his love.

Details of the next Memorial Lecture can be found in the programme for the UK MDS Forum Education Meeting (Upcoming Meetings).

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator


Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here